An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business Combination
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Polydex Pharmaceuticals Limited (POLXF) has been acquired by BioSpectra, Inc. and BioSpectra Canada, Ltd for a total consideration of $6,940,000. The acquisition resulted in the de-listing of Polydex shares. Polydex, based in Toronto, Ontario, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry and biotechnology-based products for the human pharmaceutical market.
Positive
None.
Negative
None.
TORONTO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC Pink: POLXF) (the “Company” or “Polydex”) announced today that it has consummated the Plan of Arrangement (the “Arrangement”) whereby BioSpectra, Inc. and BioSpectra Canada, Ltd (together, “BioSpectra”) acquired all of the outstanding common and preferred shares of the Company for total consideration of $6,940,000, of which US$6,924,980.02 was paid for 3,432,478 common shares outstanding and US$15,019.98 was paid for 899,400 Class B Preferred shares outstanding. The price per common share was US$2.017.
The Arrangement was effected pursuant to a statutory plan of arrangement (the “Arrangement”) under section 182 of the Ontario Business Corporations Act (the “OBCA”). The Arrangement resulted in each issued and outstanding share of Polydex being deemed transferred to BioSpectra by each Polydex shareholder, without any further act or formality on the part of the Polydex shareholder. Each Polydex shareholder as of the effective time of the Arrangement will receive consideration in exchange for their shares. Polydex shares were de-listed as of the close of trading on August 7, 2023.
Polydex, based in Toronto, Ontario, is engaged in the manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacturing and marketing of biotechnology-based products for the human pharmaceutical market. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The Company conducts its business operations through its two wholly-owned subsidiaries/divisions. The manufacture and sale of Dextran and derivative products is conducted through Dextran Products and Chemdex Inc. which is incorporated in the State of Kansas, United States.
Contact: George Usher: GU-dextran@rogers.com
The total consideration for the acquisition of Polydex Pharmaceuticals Limited is $6,940,000.
BioSpectra, Inc. and BioSpectra Canada, Ltd acquired Polydex Pharmaceuticals Limited.
Polydex Pharmaceuticals Limited is based in Toronto, Ontario.
Polydex Pharmaceuticals Limited manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry and biotechnology-based products for the human pharmaceutical market.
The business operations of Polydex Pharmaceuticals Limited are conducted through its two wholly-owned subsidiaries/divisions, Dextran Products and Chemdex Inc.
fat projects acquisition corporation, registered in cayman islands, is launching a $100m special purpose acquisition company (spac) to acquire, merge or do a business combination with a technology-led business that can solve diverse challenges in south east asia in the areas of supply chain, finance, sustainability/esg, e-commerce and big data and/or take advantage of the monetization opportunities stemming from a rapidly growing middle class and their evolving consumption needs. fat projects acquisition corporation has assembled a team of executives and entrepreneurs from some of the most successful multinational companies in the world to lead our spac. the sponsor team structure was carefully designed to provide relevant experience and networks in the region, ensure the success of the spac and the continued growth of the business it acquires. the team brings a combined 100+ years of relevant market experience in southeast asia, directly related to sustainability, finance, supply chai